Evaluation of prostate volume by transrectal ultrasonography for use in a brachytherapy program.

OBJECTIVES: To evaluate two methods of measuring the prostate volume using transrectal ultrasonography. The measurements were performed in vivo at preplanning and again preoperatively in connection with brachytherapy. The accurate measurement of the prostate volume is important in a brachytherapy program for treatment planning. METHODS: A total of 43 patients with biopsy-proven prostate cancer underwent prospective determination of the prostate volume, by one physician, using transrectal ultrasonography. Volume calculations were made at the preplanning and preoperative settings, both by a hand-held rectal probe using the prolate ellipsoid formula and by a mounted probe in a stepping device using the planimetric method. RESULTS: The coefficient of variation between the preplanning and preoperative prostate volumes with the probe holder was less than 3% compared with the hand-held probe, which was greater than 10%. The difference between the median values at the preplanning and preoperative settings by serial planimetry was 2.5 cm(3) (range 0.2 to 9.4). The difference in the median volumes between the preplanning and preoperative ellipsoid calculations was 6.7 cm(3) (range 0.3 to 38.7). The difference between the median values with the ellipsoid volume was significant (P <0.001). The Pearson correlation coefficient for all values using the planimetric method was 0.92 versus 0.58 for the ellipsoid method. The correlation coefficient was significantly greater for the planimetric method (P <0.001). CONCLUSIONS: On the basis of these data, planimetric prostate volume determination, by a single ultrasonographer, is an accurate and reproducible method with applicability to a brachytherapy program.

Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma.

BACKGROUND: Molecular mechanisms of chemotherapy resistance are present in prostate carcinoma, some of which increase after androgen ablation (AA) therapy. Therefore, the authors hypothesized that chemotherapy in patients with prostate specific antigen (PSA) progression after local therapy, before androgen ablation therapy, will have greater antitumor activity. METHODS: Twenty-three hormone-naive patients with PSA progression after prostatectomy or radiation therapy were registered in this study. Twenty-two were treated with 10 mg/m(2) of mitoxantrone initially, followed by 12 mg/m(2) every 3 weeks for a maximum of 8 cycles. Prostatectomy specimens were assessed, when possible, for topoisomerase II alpha, multidrug resistance protein MRP, and bcl-2 by immunohistochemistry. RESULTS: Twenty-two patients received a total of 131 cycles of therapy. Three patients had transient Grade 3 or 4 neutropenia without fever. During treatment, 10 of 22 patients showed a decrease in PSA, without an associated decrease in testosterone. In this group of 10 patients, the mean PSA decrease was 29% at 3 months and 43% at 6 months. Overall, 4 of 22 patients had a decrease in PSA of greater than or equal to 50%. The PSA decreased in three of seven patients whose cancer overexpressed MRP and in three of seven patients who overexpressed bcl-2. No patient with overexpression of topoisomerase II alpha (n = 4) had a decrease in PSA during the study. CONCLUSIONS: To the authors' knowledge, this is the first reported study of mitoxantrone in patients with hormone-naive prostate carcinoma and PSA progression after local therapy; mitoxantrone was safe and biochemically active, similar to prior studies in hormone refractory prostate carcinoma, suggesting that critical molecular mechanisms of chemotherapy resistance are present independent of AA. Further studies are warranted to determine whether pharmacogenomic assessment of topoisomerase II, MRP, or bcl-2 may predict for response to mitoxantrone.